Free Trial
NASDAQ:PULM

Pulmatrix Q4 2023 Earnings Report

Pulmatrix logo
$6.41 +0.03 (+0.47%)
Closing price 05/5/2025 03:58 PM Eastern
Extended Trading
$6.55 +0.14 (+2.25%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmatrix EPS Results

Actual EPS
-$0.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
$2.20 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulmatrix Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 28, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Pulmatrix's Q1 2025 earnings is scheduled for Friday, May 9, 2025

Earnings Documents

Pulmatrix Earnings Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM), a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

View Pulmatrix Profile

More Earnings Resources from MarketBeat